Medicare Now Covers GLP1 Weight Loss Drugs

A federal pilot program will let millions of Medicare beneficiaries pay $50 a month for GLP-1 weight loss drugs starting July 1, a fraction of current retail prices that run anywhere from $149 to $299 per month even with discount programs already factored in.

The Centers for Medicare & Medicaid Services calls it the Medicare GLP-1 Bridge, and the mechanics matter as much as the headline price. This is a demonstration program, not a permanent change to Part D, and it sits outside standard Medicare drug coverage entirely. That structural choice shapes everything from who qualifies to how the savings actually accrue over the program's 18 month run, which ends December 31, 2027.

The Math Behind the $50 Copay

Run the numbers over the full program window and the gap becomes stark. At $50 per month for 18 months, a beneficiary pays roughly $900 total. Compare that to $200 per month, a price point well within range for these drugs once dosage increases or a beneficiary shops at a provider without discount pricing, and the same 18 months costs $3,600. That is a $2,700 difference for identical drugs, identical duration, different payment channel.

Context on current pricing makes the contrast sharper. TrumpRx, the discount platform the Trump administration launched, prices the Wegovy tablet at a minimum of $149 per month and the Zepbound Kwikpen at a minimum of $299. GoodRx lists Foundayo as low as $149 per month and the Wegovy injection at a $199 floor. Those are starting prices only. Actual costs climb well past those minimums as patients titrate to higher doses, meaning the $2,700 gap calculated above is likely conservative for many participants.

Because the program operates outside standard Part D payment structures, the $50 copay does not count toward annual deductibles or out of pocket maximums. It also will not interact with the Medicare Prescription Payment Plan or with low income subsidy programs. Every eligible participant pays the same flat $50, regardless of plan design or income tier, which simplifies the pricing model but also means the program doesn't layer additional subsidy on top for the lowest income beneficiaries.

Sizing the Eligible Population

3.8 million is the figure KFF, the health policy research organization, derives from 2023 Medicare data as the estimated pool of eligible beneficiaries. Chris Klomp, director of Medicare and chief counselor at HHS, has offered a narrower initial estimate of